
Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer’s disease
Keywords: ریواستیگمین; Organogel; Rivastigmine; Alzheimer’s disease; Pharmacokinetic; Biocompatibility; AChE inhibition